AKR1C2 is a cytosolic NADPH-dependent aldo-keto reductase that catalyzes the reduction of ketosteroids to hydroxysteroids, with broad substrate specificity producing primarily 3α-hydroxysteroids but also 3β-, 17β-, and 20α-hydroxysteroids 1. The enzyme plays critical roles in three major metabolic pathways: (1) Male sex determination via the 'backdoor' androgen synthesis pathway, where it converts 5α-dihydroprogesterone to allopregnanolone, ultimately generating 5α-dihydrotestosterone necessary for testicular differentiation 2; (2) Neurosteroid biosynthesis, reducing precursors to neuroactive steroids like allopregnanolone that modulate GABAergic neurotransmission 3; and (3) Androgen catabolism, inactivating 5α-dihydrotestosterone and progesterone into less active metabolites 2. Clinically, AKR1C2 dysfunction associates with 46,XY sex reversal. In cancer biology, AKR1C2 shows prognostic significance in breast cancer, correlating with favorable outcomes through regulation of intratumoral progesterone metabolism 4. Conversely, AKR1C2 knockdown promotes ferroptosis and inhibits proliferation and migration in lung cancer cells 5, while reduced AKR1C2 expression in prostate cancer promotes androgen retention and tumor progression 2. The enzyme's involvement in ROS elimination and chemotherapy resistance indicates dual roles in malignancy depending on tumor context 1.